The hypervalent orphan drug, ‘Soliris’, has been a target for a clinical trial to improve indication in Korea

A clinical trial will be conducted to improve indication for the paroxysmal nocturnal hemoglobinuria (PHN) treatment ‘Soliris (generic name: eculizumab)’ reaching KRW 400 million administration expenses every year.

The Ministry of Food and Drug Safety has approved the Phase 3 clinical trial of Soliris at the Quintiles Transnational Korea on the 4^th.

The clinical trial is a random allocation, ...